Results 191 to 200 of about 92,046 (305)

Progressively exploring and assessing the prognosis of bladder urothelial cancer based on the microenvironment through the integration of multiple databases. [PDF]

Front Mol Biosci
Zou X, Li Y, Peng X, Gu C, Wang Q.
europepmc   +1 more source

Validation of the diagnostic accuracy of a urine‐based DNA methylation marker test in patients with upper urinary tract lesions

BJUI Compass, Volume 7, Issue 3, March 2026.
Abstract Objectives This study aims to validate the diagnostic accuracy of a novel urine‐based DNA methylation test in patients with suspected upper tract urothelial carcinoma (UTUC) on CT urography and to assess its potential to eliminate the need for diagnostic ureterorenoscopy (URS) in selected patients, expedite treatment and identify high‐grade ...
Christian Daniel Fankhauser, Kilian Röthlin, Philipp Baumeister, Agostino Mattei, Paolo Piatti, Yap Ching Chew, Ernest Kaufmann   +6 more
wiley   +1 more source

Staging metastatic urothelial cancer with Nectin-4 imaging using Gallium-68-N188 PET/CT. [PDF]

BJU Int
Miederer M, Pretze M, Abbate E, Hartig A, do Mar Ferreira Machado J, Böhm K, Sommer U, Hoberück S, Bundschuh RA, Kotzerke J, Thomas C.   +10 more
europepmc   +1 more source

Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study

British Journal of Clinical Pharmacology, Volume 92, Issue 3, Page 980-996, March 2026.
Aims In the AEGEAN study, perioperative durvalumab plus platinum‐based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non‐small‐cell lung cancer (NSCLC) demonstrated a favourable benefit–risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure–response (ER) relationships of durvalumab in patients ...
Xiaoying Zhao, Junjie Ding, Jiajia Zhao, Ling Zhang, Aburough Abegesah, Yu‐qian Zhang, Cathy O'Brien, Gary J. Doherty, Allen C. Chen, KyoungSoo Lim, Song Ren, Peiming Ma, Diansong Zhou   +12 more
wiley   +1 more source

Recent advances in understanding the role of sex hormone receptors in urothelial cancer. [PDF]

Oncol Res
Elahi Najafi MA, Matsukawa T, Miyamoto H.   +2 more
europepmc   +1 more source

Are There Socio‐Demographic Inequalities in the Utilisation of Tumour and ctDNA Somatic Mutation Testing in Solid Tumours? A Systematic Review

Cancer Medicine, Volume 15, Issue 3, March 2026.
This systematic review investigates whether inequalities exist in the utilisation of tumour and ctDNA somatic mutation testing in solid tumours. The review concludes that, across tumour types, testing modalities and socio‐demographic factors, inequalities exist and require further exploration.
Sarah Rae, Annie Baldwin, Maria Julia Lagonera, Ruth Norris, Alastair Greystoke, Linda Sharp   +5 more
wiley   +1 more source

Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin-Related Dermatologic Events in Patients with Advanced Urothelial Cancer. [PDF]

Cancer Res Commun
Vlachou E, Johnson BA, McConkey DJ, Hahn NM, Jing Y, Russell S, Stairiker D, Rosen A, Casciola-Rosen LA, Hoffman-Censits J.   +9 more
europepmc   +1 more source

Vitamin D and Bladder Cancer Risk: An Umbrella Review and Second Order Meta‐Analysis

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Introduction Bladder cancer is a common malignancy with a high recurrence rate, posing a significant public health burden. Beyond its role in bone health, vitamin D has been suggested to influence cancer risk, including bladder cancer. Aim To evaluate the association between serum vitamin D levels, dietary intake, and supplementation with ...
Stefano Mancin, Gaetano Ferrara, Sara Morales Palomares, Sofia Matteucci, Alice Maria Santagostino, Giulia Ferrari, Mauro Parozzi, Fabio Petrelli, Rodolfo Hurle, Marco Sguanci, Giovanni Cangelosi   +10 more
wiley   +1 more source

Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom. [PDF]

BMJ Open
Wu Q, Li Q, Qin Y.
europepmc   +1 more source

Genetic Alterations Involved in Immune Escape Mechanisms of Circulating Tumour Cells in Colorectal Carcinogenesis

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT In colorectal cancer (CRC), circulating tumour cells (CTCs) employ genetic alterations to dodge the body's immune system. These alterations occur in specific “driver” genes, including KRAS, BRAF, p53, MYC, APC and PTEN. Changes in these genes can control how the tumour interacts with the immune system and influence the expression of immune ...
Sharmin Aktar, Matthew Masoudi, Dilpreet Moti, Vinod Gopalan, Farhadul Islam, Alfred King‐yin Lam   +5 more
wiley   +1 more source